If Recursion's TechBio strategy achieves its potential, this stock could do a lot more than double over the next decade and beyond. Should you invest $1,000 in Recursion Pharmaceuticals right now?

That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...

By applying a proprietary OS to drug discovery, Recursion is turning drug discovery from sequential testing into a search problem.

With a technique called cell painting, Recursion Pharmaceuticals is creating a really big picture of morphology of cells in the body. But that's just the beginning; the really hard part is knowing ...

Recursion has more expressive power than iterative looping constructs. I say this because a while loop is equivalent to a tail recursive function and recursive functions need not be tail recursive.

EW caught up with Crouch prior to the book’s publication on the hype behind Recursion, why it was such a personal project from him, and exactly what we can expect from the Netflix adaptation.

Recursion Pharmaceuticals is reshaping drug discovery with AI, strategic partnerships, and financial discipline for long-term investors. Explore more details here.

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results.

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of ...